DiscSeal is a viscous material injected percutaneously into the intervertebral diseased disc of patients under local anesthesia.
Beginning in February, the study is examining the safety and efficacy of DiscSeal in patients suffering from lumbar pain.
Results at the 90-day midpoint indicate a reduction in lumbar pain, leg pain and disability.
Led by James Yu, MD, the trial is examining the treatment in six patients with lumbar pain caused by discogenic disease who have not responded to first-line medical therapy.
SpineOvations will report final study findings in late summer.
Click here to view 90-day interim results from the study.
More articles on devices:
How 5 spine practices are proceeding with recovery plans
New Jersey hospital opens Institute for Robotic Surgery
Centinel Spine gets OK for manufacturing transfer of prodisc systems
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
